Join the Semaglutide group to help and get support from people like you.
Semaglutide News
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 – Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published online July 21 in...
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 – For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 – For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 – For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1 receptor agonists (GLP-1...
GLP-1 Receptor Agonists May Improve Outcomes in Idiopathic Intracranial Hypertension
MONDAY, July 21, 2025 – For patients with idiopathic intracranial hypertension (IIH), glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is associated with improved clinical outcomes...
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 – In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy care in individuals...
Diabetic Women Should Be Asked About Desire For Kids At Every Doctor's Visit, Guidelines Say
FRIDAY, July 18, 2025 — Doctors should ask diabetic women at every visit about their intention to have a child, to make sure they get the appropriate care prior to conception, new guidelines say. T...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 – For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux disease (GERD)...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 – Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is independently associated with...
Diet, Exercise Can Help GLP-1 Patients Who Miss Doses
TUESDAY, July 15, 2025 — It can sometimes be tough to fill prescriptions for GLP-1 drugs like Wegovy and Zepbound, given the overwhelming popularity of the breakthrough weight-loss meds. But people w...
Certain Factors May Predict Weight Fluctuations After GLP-1 Receptor Agonist Treatment
TUESDAY, July 15, 2025 – For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study...
GLP-1 Drugs Increase Risk Of Acid Reflux, GERD
TUESDAY, July 15, 2025 — Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says. People with type 2 diabetes were more likely to suffer f...
Menopause Hormone Therapy Boosts GLP-1 Drug Effectiveness, Researchers Say
MONDAY, July 14, 2025 — Good news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new s...
Rival GLP-1 Weight-Loss Drug, Ecnoglutide, Emerges From China
TUESDAY, June 24, 2025 — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic/Wegovy and Zepbound, clinical trial results show. Ecnoglutide helped p...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2